The cytokines of pulmonary fibrosis: Much learned, much more to learn

Cytokine

Volumn 74, Issue 1, 2015, Pages 88-100

  Luzina, Irina G ^a,b   Todd, Nevins W ^a,b   Sundararajan, Sripriya ^b   Atamas, Sergei P ^a,b  

^a BALTIMORE VA MEDICAL CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Cytokines; Fibrosis; Growth factors; Lung; Myofibroblasts

Indexed keywords

AMPHIREGULIN; CCL18 CHEMOKINE; CONNECTIVE TISSUE GROWTH FACTOR; CYSTEINE RICH PROTEIN 61; CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 20; INTERLEUKIN 22; INTERLEUKIN 25; INTERLEUKIN 33; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 9; MONOCYTE CHEMOTACTIC PROTEIN 1; ONCOSTATIN M; PLATELET DERIVED GROWTH FACTOR; SCATTER FACTOR; SOMATOMEDIN; STEM CELL FACTOR; STROMAL CELL DERIVED FACTOR 1; THYMIC STROMAL LYMPHOPOIETIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; SIGNAL PEPTIDE;

APOPTOSIS; BLOOD CLOTTING DISORDER; CYTOKINE PRODUCTION; HUMAN; IMMUNOREACTIVITY; IMMUNOREGULATION; INTRACELLULAR SIGNALING; LUNG FIBROSIS; MOLECULAR PATHOLOGY; MYOFIBROBLAST; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; REVIEW; TH2 CELL; ANIMAL; EXTRACELLULAR MATRIX; IMMUNOLOGY; INFLAMMATION; METABOLISM; PATHOLOGY; PHYSIOLOGY; PULMONARY FIBROSIS;

ANIMALS; CYTOKINES; EXTRACELLULAR MATRIX; HUMANS; INFLAMMATION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; PULMONARY FIBROSIS;

EID: 84930181008     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2014.11.008     Document Type: Review

References (243)

1. Canady J., Karrer S., Fleck M., Bosserhoff A.K. Fibrosing connective tissue disorders of the skin: molecular similarities and distinctions. J Dermatol Sci 2013, 70(3):151-158.
2. Smith G.P., Chan E.S. Molecular pathogenesis of skin fibrosis: insight from animal models. Curr Rheumatol Rep 2010, 12(1):26-33.
3. Pellicoro A., Ramachandran P., Iredale J.P., Fallowfield J.A. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol 2014, 14(3):181-194.
4. Kocabayoglu P., Friedman S.L. Cellular basis of hepatic fibrosis and its role in inflammation and cancer. Front Biosci (Schol Ed) 2013, 5:217-230.
5. Poynard T., Lebray P., Ingiliz P., Varaut A., Varsat B., Ngo Y., et al. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest). BMC Gastroenterol 2010, 10:40.
6. Liu Y. Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol 2011, 7(12):684-696.
7. Farris A.B., Colvin R.B. Renal interstitial fibrosis: mechanisms and evaluation. Curr Opin Nephrol Hypertens 2012, 21(3):289-300.
8. Kong P., Christia P., Frangogiannis N.G. The pathogenesis of cardiac fibrosis. Cell Mol Life Sci 2014, 71(4):549-574.
9. Krenning G., Zeisberg E.M., Kalluri R. The origin of fibroblasts and mechanism of cardiac fibrosis. J Cell Physiol 2010, 225(3):631-637.
10. Raghu G., Chen S.Y., Yeh W.S., Maroni B., Li Q., Lee Y.C., et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. Lancet Respir Med 2014.
11. Olson A.L., Swigris J.J., Lezotte D.C., Norris J.M., Wilson C.G., Brown K.K. Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med 2007, 176(3):277-284.
12. Raghu G., Weycker D., Edelsberg J., Bradford W.Z., Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006, 174(7):810-816.
13. Schwartz M.I., King T.E. Interstitial lung disease 2010, People's Medical Publishing House-USA, Shelton, CT. 5th ed.
14. Fischer A., du Bois R. Interstitial lung disease in connective tissue disorders. Lancet 2012, 380(9842):689-698.
15. Herzog E.L., Mathur A., Tager A.M., Feghali-Bostwick C., Schneider F., Varga J. Interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct?. Arthritis Rheumatol 2014.
16. Steen V.D., Medsger T.A. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007, 66(7):940-944.
17. Vij R., Strek M.E. Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. Chest 2013, 143(3):814-824.
18. Solomon J.J., Olson A.L., Fischer A., Bull T., Brown K.K., Raghu G. Scleroderma lung disease. Eur Respir Rev 2013, 22(127):6-19.
19. Hu B., Phan S.H. Myofibroblasts. Curr Opin Rheumatol 2013, 25(1):71-77.
20. Kramann R., DiRocco D.P., Humphreys B.D. Understanding the origin, activation and regulation of matrix-producing myofibroblasts for treatment of fibrotic disease. J Pathol 2013, 231(3):273-289.
21. Al-Muhsen S., Johnson J.R., Hamid Q. Remodeling in asthma. J Allergy Clin Immunol 2011, 128(3):451-462. quiz 463-454.
22. Hirota N., Martin J.G. Mechanisms of airway remodeling. Chest 2013, 144(3):1026-1032.
23. Barker A.F., Bergeron A., Rom W.N., Hertz M.I. Obliterative bronchiolitis. N Engl J Med 2014, 370(19):1820-1828.
24. Arakawa H., Johkoh T., Honma K., Saito Y., Fukushima Y., Shida H., et al. Chronic interstitial pneumonia in silicosis and mix-dust pneumoconiosis: its prevalence and comparison of CT findings with idiopathic pulmonary fibrosis. Chest 2007, 131(6):1870-1876.
25. Camus P., Fanton A., Bonniaud P., Camus C., Foucher P. Interstitial lung disease induced by drugs and radiation. Respiration 2004, 71(4):301-326.
26. Nathan S.D., Shlobin O.A., Weir N., Ahmad S., Kaldjob J.M., Battle E., et al. Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest 2011, 140(1):221-229.
27. King T.E., Bradford W.Z., Castro-Bernardini S., Fagan E.A., Glaspole I., Glassberg M.K., et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014, 370(22):2083-2092.
28. Kalluri R., Neilson E.G. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003, 112(12):1776-1784.
29. Lamouille S., Xu J., Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 2014, 15(3):178-196.
30. Bartis D., Mise N., Mahida R.Y., Eickelberg O., Thickett D.R. Epithelial-mesenchymal transition in lung development and disease: does it exist and is it important?. Thorax 2014, 69(8):760-765.
31. Rock J.R., Barkauskas C.E., Cronce M.J., Xue Y., Harris J.R., Liang J., et al. Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition. Proc Natl Acad Sci U S A 2011, 108(52):E1475-1483.
32. Grabias B.M., Konstantopoulos K. Epithelial-mesenchymal transition and fibrosis are mutually exclusive reponses in shear-activated proximal tubular epithelial cells. FASEB J 2012, 26(10):4131-4141.
33. Hardie W.D., Hagood J.S., Dave V., Perl A.K., Whitsett J.A., Korfhagen T.R., et al. Signaling pathways in the epithelial origins of pulmonary fibrosis. Cell Cycle 2010, 9(14):2769-2776.
34. Piera-Velazquez S., Li Z., Jimenez S.A. Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders. Am J Pathol 2011, 179(3):1074-1080.
35. Karki S., Surolia R., Hock T.D., Guroji P., Zolak J.S., Duggal R., et al. Wilms' tumor 1 (Wt1) regulates pleural mesothelial cell plasticity and transition into myofibroblasts in idiopathic pulmonary fibrosis. FASEB J 2014, 28(3):1122-1131.
36. Li Y., Wang J., Asahina K. Mesothelial cells give rise to hepatic stellate cells and myofibroblasts via mesothelial-mesenchymal transition in liver injury. Proc Natl Acad Sci U S A 2013, 110(6):2324-2329.
37. Bellaye P.-S., Burgy O., Colas J., Fabre A., Marchal-Somme J., Crestani B., et al. Anti-fibrotic role of αB-crystallin inhibition in pleural and subpleural fibrosis. Am J Respir Cell Mol Biol 2014.
38. Lin S.L., Kisseleva T., Brenner D.A., Duffield J.S. Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am J Pathol 2008, 173(6):1617-1627.
39. Wu C.F., Chiang W.C., Lai C.F., Chang F.C., Chen Y.T., Chou Y.H., et al. Transforming growth factor beta-1 stimulates profibrotic epithelial signaling to activate pericyte-myofibroblast transition in obstructive kidney fibrosis. Am J Pathol 2013, 182(1):118-131.
40. Mederacke I., Hsu C.C., Troeger J.S., Huebener P., Mu X., Dapito D.H., et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat Commun 2013, 4:2823.
41. Hung C., Linn G., Chow Y.H., Kobayashi A., Mittelsteadt K., Altemeier W.A., et al. Role of lung pericytes and resident fibroblasts in the pathogenesis of pulmonary fibrosis. Am J Respir Crit Care Med 2013, 188(7):820-830.
42. Cencetti F., Bernacchioni C., Nincheri P., Donati C., Bruni P. Transforming growth factor-beta1 induces transdifferentiation of myoblasts into myofibroblasts via up-regulation of sphingosine kinase-1/S1P3 axis. Mol Biol Cell 2010, 21(6):1111-1124.
43. Ono Y., Sensui H., Okutsu S., Nagatomi R. Notch2 negatively regulates myofibroblastic differentiation of myoblasts. J Cell Physiol 2007, 210(2):358-369.
44. Bucala R. Review series-inflammation & fibrosis. Fibrocytes and fibrosis. QJM 2012, 105(6):505-508.
45. Reilkoff R., Mathur A., Herzog E.L. Fibrocytes in scleroderma lung fibrosis. Systemic sclerosis - an update on the aberrant immune system and clinical features 2012, InTech.
46. Kulasekaran P., Scavone C.A., Rogers D.S., Arenberg D.A., Thannickal V.J., Horowitz J.C. Endothelin-1 and transforming growth factor-beta1 independently induce fibroblast resistance to apoptosis via AKT activation. Am J Respir Cell Mol Biol 2009, 41(4):484-493.
47. Wynes M.W., Edelman B.L., Kostyk A.G., Edwards M.G., Coldren C., Groshong S.D., et al. Increased cell surface Fas expression is necessary and sufficient to sensitize lung fibroblasts to Fas ligation-induced apoptosis: implications for fibroblast accumulation in idiopathic pulmonary fibrosis. J Immunol 2011, 187(1):527-537.
48. Thannickal V.J., Horowitz J.C. Evolving concepts of apoptosis in idiopathic pulmonary fibrosis. Proc Am Thorac Soc 2006, 3(4):350-356.
49. Tomasek J.J., Haaksma C.J., Schwartz R.J., Howard E.W. Whole animal knockout of smooth muscle alpha-actin does not alter excisional wound healing or the fibroblast-to-myofibroblast transition. Wound Repair Regen 2013, 21(1):166-176.
50. Takeji M., Moriyama T., Oseto S., Kawada N., Hori M., Imai E., et al. Smooth muscle alpha-actin deficiency in myofibroblasts leads to enhanced renal tissue fibrosis. J Biol Chem 2006, 281(52):40193-40200.
51. Rodriguez A., Friman T., Kowanetz M., van Wieringen T., Gustafsson R., Sundberg C. Phenotypical differences in connective tissue cells emerging from microvascular pericytes in response to overexpression of PDGF-B and TGF-beta1 in normal skin in vivo. Am J Pathol 2013, 182(6):2132-2146.
52. Kaufman J., Graf B.A., Leung E.C., Pollock S.J., Koumas L., Reddy S.Y., et al. Fibroblasts as sentinel cells: role of the CDcd40-CDcd40 ligand system in fibroblast activation and lung inflammation and fibrosis. Chest 2001, 120(Suppl. 1):53S-55S.
53. Smith R.S., Smith T.J., Blieden T.M., Phipps R.P. Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation. Am J Pathol 1997, 151(2):317-322.
54. Flaherty K.R., Thwaite E.L., Kazerooni E.A., Gross B.H., Toews G.B., Colby T.V., et al. Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax 2003, 58(2):143-148.
55. Todd N.W., Scheraga R.G., Galvin J.R., Iacono A.T., Britt E.J., Luzina I.G., et al. Lymphocyte aggregates persist and accumulate in the lungs of patients with idiopathic pulmonary fibrosis. J Inflamm Res 2013, 6:63-70.
56. Todd N.W., Luzina I.G., Atamas S.P. Molecular and cellular mechanisms of pulmonary fibrosis. Fibrogenesis Tissue Repair 2012, 5(1):11.
57. Atamas S.P., Fontenot A.P. Regulatory T cells and lung fibrosis: a good cell gone bad. Am J Respir Crit Care Med 2011, 184(11):1224-1226.
58. Luzina I.G., Todd N.W., Iacono A.T., Atamas S.P. Roles of T lymphocytes in pulmonary fibrosis. J Leukocyte Biol 2008, 83(2):237-244.
59. Ud-Din S., Volk S., Bayat A. Regenerative healing, scar-free healing and scar formation across the species: current concepts and future perspectives. Exp Dermatol 2014.
60. Godwin J.W., Rosenthal N. Scar-free wound healing and regeneration in amphibians: immunological influences on regenerative success. Differentiation 2014, 87(1-2):66-75.
61. Harty M., Neff A.W., King M.W., Mescher A.L. Regeneration or scarring: an immunologic perspective. Dev Dyn 2003, 226(2):268-279.
62. Franchini A., Bertolotti E. The thymus and skin wound healing in Xenopus laevis adults. Acta Histochem 2014.
63. Bertolotti E., Malagoli D., Franchini A. Skin wound healing in different aged Xenopus laevis. J Morphol 2013, 274(8):956-964.
64. Komura K., Fujimoto M., Yanaba K., Matsushita T., Matsushita Y., Horikawa M., et al. Blockade of CD40/CD40 ligand interactions attenuates skin fibrosis and autoimmunity in the tight-skin mouse. Ann Rheum Dis 2008, 67(6):867-872.
65. Atamas S.P., Luzina I.G., Dai H., Wilt S.G., White B. Synergy between CD40 ligation and IL-4 on fibroblast proliferation involves IL-4 receptor signaling. J Immunol 2002, 168(3):1139-1145.
66. Hao Z., Hampel B., Yagita H., Rajewsky K. T cell-specific ablation of Fas leads to Fas ligand-mediated lymphocyte depletion and inflammatory pulmonary fibrosis. J Exp Med 2004, 199(10):1355-1365.
67. Hecker L., Vittal R., Jones T., Jagirdar R., Luckhardt T.R., Horowitz J.C., et al. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat Med 2009, 15(9):1077-1081.
68. Jiang F., Liu G.S., Dusting G.J., Chan E.C. NADPH oxidase-dependent redox signaling in TGF-beta-mediated fibrotic responses. Redox Biol 2014, 2:267-272.
69. Sakai N., Tager A.M. Fibrosis of two: epithelial cell-fibroblast interactions in pulmonary fibrosis. Biochim Biophys Acta 2013, 1832(7):911-921.
70. Marinkovic A., Mih J.D., Park J.A., Liu F., Tschumperlin D.J. Improved throughput traction microscopy reveals pivotal role for matrix stiffness in fibroblast contractility and TGF-beta responsiveness. Am J Physiol Lung Cell Mol Physiol 2012, 303(3):L169-180.
71. Hinz B. Mechanical aspects of lung fibrosis: a spotlight on the myofibroblast. Proc Am Thorac Soc 2012, 9(3):137-147.
72. Gu H., Mickler E.A., Cummings O.W., Sandusky G.E., Weber D.J., Gracon A., et al. Crosstalk between TGF-beta1 and complement activation augments epithelial injury in pulmonary fibrosis. FASEB J 2014.
73. Prasad S., Hogaboam C.M., Jarai G. Deficient repair response of IPF fibroblasts in a co-culture model of epithelial injury and repair. Fibrogenesis Tissue Repair 2014, 7:7.
74. Williams K.J. Gammaherpesviruses and pulmonary fibrosis: evidence from humans, horses, and rodents. Vet Pathol 2014, 51(2):372-384.
75. Deng X., Mercer P.F., Scotton C.J., Gilchrist A., Chambers R.C. Thrombin induces fibroblast CCL2/JE production and release via coupling of PAR1 to Galphaq and cooperation between ERK1/2 and Rho kinase signaling pathways. Mol Biol Cell 2008, 19(6):2520-2533.
76. Jenkins R.G., Su X., Su G., Scotton C.J., Camerer E., Laurent G.J., et al. Ligation of protease-activated receptor 1 enhances alpha(v)beta6 integrin-dependent TGF-beta activation and promotes acute lung injury. J Clin Invest 2006, 116(6):1606-1614.
77. Bogatkevich G.S., Ludwicka-Bradley A., Nietert P.J., Akter T., van Ryn J., Silver R.M. Antiinflammatory and antifibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease. Arthritis Rheum 2011, 63(5):1416-1425.
78. Del Principe D., Lista P., Malorni W., Giammarioli A.M. Fibroblast autophagy in fibrotic disorders. J Pathol 2013, 229(2):208-220.
79. Moore B.B, Lawson W.E., Oury T.D., Sisson T.H., Raghavendran K., Hogaboam C.M. Animal models of fibrotic lung disease. Am J Respir Cell Mol Biol 2013, 49(2):167-179.
80. Moeller A., Ask K., Warburton D., Gauldie J., Kolb M. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis?. Int J Biochem Cell Biol 2008, 40(3):362-382.
81. Dinarello C.A. Infection, fever, and exogenous and endogenous pyrogens: some concepts have changed. J Endotoxin Res 2004, 10(4):201-222.
82. COPE. Horst ibelgaufts' cytokines & cells online pathfinder encyclopaedia. . http://www.copewithcytokines.de/.
83. Lagares D., Busnadiego O., Garcia-Fernandez R.A., Lamas S., Rodriguez-Pascual F. Adenoviral gene transfer of endothelin-1 in the lung induces pulmonary fibrosis through the activation of focal adhesion kinase. Am J Respir Cell Mol Biol 2012, 47(6):834-842.
84. Fonseca C., Abraham D., Renzoni E.A. Endothelin in pulmonary fibrosis. Am J Respir Cell Mol Biol 2011, 44(1):1-10.
85. Jain M., Budinger G.R., Lo A., Urich D., Rivera S.E., Ghosh A.K., et al. Leptin promotes fibroproliferative acute respiratory distress syndrome by inhibiting peroxisome proliferator-activated receptor-gamma. Am J Respir Crit Care Med 2011, 183(11):1490-1498.
86. Huang X., Gai Y., Yang N., Lu B., Samuel C.S., Thannickal V.J., et al. Relaxin regulates myofibroblast contractility and protects against lung fibrosis. Am J Pathol 2011, 179(6):2751-2765.
87. Samuel C.S., Zhao C., Bathgate R.A., Bond C.P., Burton M.D., Parry L.J., et al. Relaxin deficiency in mice is associated with an age-related progression of pulmonary fibrosis. FASEB J 2003, 17(1):121-123.
88. Marut W., Kavian N., Servettaz A., Hua-Huy T., Nicco C., Chereau C., et al. Amelioration of systemic fibrosis in mice by angiotensin II receptor blockade. Arthritis Rheum 2013, 65(5):1367-1377.
89. Stawski L., Han R., Bujor A.M., Trojanowska M. Angiotensin II induces skin fibrosis: a novel mouse model of dermal fibrosis. Arthritis Res Ther 2012, 14(4):R194.
90. Tager A.M., LaCamera P., Shea B.S., Campanella G.S., Selman M., Zhao Z., et al. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med 2008, 14(1):45-54.
91. Huang S.K., Peters-Golden M. Eicosanoid lipid mediators in fibrotic lung diseases: ready for prime time?. Chest 2008, 133(6):1442-1450.
92. Kowal-Bielecka O., Kowal K., Distler O., Rojewska J., Bodzenta-Lukaszyk A., Michel B.A., et al. Cyclooxygenase- and lipoxygenase-derived eicosanoids in bronchoalveolar lavage fluid from patients with scleroderma lung disease: an imbalance between proinflammatory and antiinflammatory lipid mediators. Arthritis Rheum 2005, 52(12):3783-3791.
93. Fabre A., Marchal-Somme J., Marchand-Adam S., Quesnel C., Borie R., Dehoux M., et al. Modulation of bleomycin-induced lung fibrosis by serotonin receptor antagonists in mice. Eur Respir J 2008, 32(2):426-436.
94. Zhou Y., Schneider D.J., Morschl E., Song L., Pedroza M., Karmouty-Quintana H., et al. Distinct roles for the A2B adenosine receptor in acute and chronic stages of bleomycin-induced lung injury. J Immunol 2011, 186(2):1097-1106.
95. Arras M., Louahed J., Simoen V., Barbarin V., Misson P., van den Brule S., et al. B lymphocytes are critical for lung fibrosis control and prostaglandin E2 regulation in IL-9 transgenic mice. Am J Respir Cell Mol Biol 2006, 34(5):573-580.
96. Kudo H., Jinnin M., Asano Y., Trojanowska M., Nakayama W., Inoue K., et al. Decreased interleukin-20 expression in scleroderma skin contributes to cutaneous fibrosis. Arthritis Rheumatol 2014, 66(6):1636-1647.
97. Ding L., Dolgachev V., Wu Z., Liu T., Nakashima T., Ullenbruch M., et al. Essential role of stem cell factor-c-Kit signalling pathway in bleomycin-induced pulmonary fibrosis. J Pathol 2013, 230(2):205-214.
98. Zhou Y., Lee J.Y., Lee C.M., Cho W.K., Kang M.J., Koff J.L., et al. Amphiregulin, an epidermal growth factor receptor ligand, plays an essential role in the pathogenesis of transforming growth factor-beta-induced pulmonary fibrosis. J Biol Chem 2012, 287(50):41991-42000.
99. Fukumoto J., Harada C., Kawaguchi T., Suetsugu S., Maeyama T., Inoshima I., et al. Amphiregulin attenuates bleomycin-induced pneumopathy in mice. Am J Physiol Lung Cell Mol Physiol 2010, 298(2):L131-L138.
100. Yang L., Kwon J., Popov Y., Gajdos G.B., Ordog T., Brekken R.A., et al. Vascular endothelial growth factor promotes fibrosis resolution and repair in mice. Gastroenterology 2014, 146(5):1339-1350. e1331.
101. Maurer B., Distler A., Suliman Y.A., Gay R.E., Michel B.A., Gay S., et al. Vascular endothelial growth factor aggravates fibrosis and vasculopathy in experimental models of systemic sclerosis. Ann Rheum Dis 2014, 73(10):1880-1887.
102. van Bon L., Affandi A.J., Broen J., Christmann R.B., Marijnissen R.J., Stawski L., et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med 2014, 370(5):433-443.
103. Madala S.K., Korfhagen T.R., Schmidt S., Davidson C., Edukulla R., Ikegami M., et al. Inhibition of the alphavbeta6 integrin leads to limited alteration of TGF-alpha-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2014, 306(8):L726-735.
104. Radaev S., Zou Z., Huang T., Lafer E.M., Hinck A.P., Sun P.D. Ternary complex of transforming growth factor-beta1 reveals isoform-specific ligand recognition and receptor recruitment in the superfamily. J Biol Chem 2010, 285(19):14806-14814.
105. Ask K., Bonniaud P., Maass K., Eickelberg O., Margetts P.J., Warburton D., et al. Progressive pulmonary fibrosis is mediated by TGF-beta isoform 1 but not TGF-beta3. Int J Biochem Cell Biol 2008, 40(3):484-495.
106. Penn J.W., Grobbelaar A.O., Rolfe K.J. The role of the TGF-beta family in wound healing, burns and scarring: a review. Int J Burns Trauma 2012, 2(1):18-28.
107. Sanjabi S., Zenewicz L.A., Kamanaka M., Flavell R.A. Anti-inflammatory and pro-inflammatory roles of TGF-beta, IL-10, and IL-22 in immunity and autoimmunity. Curr Opin Pharmacol 2009, 9(4):447-453.
108. Henderson N.C., Arnold T.D., Katamura Y., Giacomini M.M., Rodriguez J.D., McCarty J.H., et al. Targeting of alphav integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med 2013, 19(12):1617-1624.
109. Gerber E.E., Gallo E.M., Fontana S.C., Davis E.C., Wigley F.M., Huso D.L., et al. Integrin-modulating therapy prevents fibrosis and autoimmunity in mouse models of scleroderma. Nature 2013, 503(7474):126-130.
110. Mimura Y., Ihn H., Jinnin M., Asano Y., Yamane K., Tamaki K. Constitutive thrombospondin-1 overexpression contributes to autocrine transforming growth factor-beta signaling in cultured scleroderma fibroblasts. Am J Pathol 2005, 166(5):1451-1463.
111. Chen Y., Leask A., Abraham D.J., Kennedy L., Shi-Wen X., Denton C.P., et al. Thrombospondin 1 is a key mediator of transforming growth factor beta-mediated cell contractility in systemic sclerosis via a mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK)-dependent mechanism. Fibrogenesis Tissue Repair 2011, 4(1):9.
112. Evrard S., Bluteau O., Tulliez M., Rameau P., Gonin P., Zetterberg E., et al. Thrombospondin-1 is not the major activator of TGF-beta1 in thrombopoietin-induced myelofibrosis. Blood 2011, 117(1):246-249.
113. Ezzie M.E., Piper M.G., Montague C., Newland C.A., Opalek J.M., Baran C., et al. Thrombospondin-1-deficient mice are not protected from bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 2011, 44(4):556-561.
114. Trojanowska M. Noncanonical transforming growth factor beta signaling in scleroderma fibrosis. Curr Opin Rheumatol 2009, 21(6):623-629.
115. Nakerakanti S., Trojanowska M. The role of TGF-beta receptors in fibrosis. Open Rheumatol J 2012, 6:156-162.
116. Chacko B.M., Qin B.Y., Tiwari A., Shi G., Lam S., Hayward L.J., et al. Structural basis of heteromeric smad protein assembly in TGF-beta signaling. Mol Cell 2004, 15(5):813-823.
117. Duan W.J., Yu X., Huang X.R., Yu J.W., Lan H.Y. Opposing roles for Smad2 and Smad3 in peritoneal fibrosis in Vivo and in Vitro. Am J Pathol 2014, 184(8):2275-2284.
118. Meng X.M., Huang X.R., Chung A.C., Qin W., Shao X., Igarashi P., et al. Smad2 protects against TGF-beta/Smad3-mediated renal fibrosis. J Am Soc Nephrol 2010, 21(9):1477-1487.
119. Jung S.M., Lee J.H., Park J., Oh Y.S., Lee S.K., Park J.S., et al. Smad6 inhibits non-canonical TGF-beta1 signalling by recruiting the deubiquitinase A20 to TRAF6. Nat Commun 2013, 4:2562.
120. Schwartze J.T., Becker S., Sakkas E., Wujak L.A., Niess G., Usemann J., et al. Glucocorticoids recruit Tgfbr3 and Smad1 to shift transforming growth factor-beta signaling from the Tgfbr1/Smad2/3 axis to the Acvrl1/Smad1 axis in lung fibroblasts. J Biol Chem 2014, 289(6):3262-3275.
121. Nakerakanti S.S., Bujor A.M., Trojanowska M. CCN2 is required for the TGF-beta induced activation of Smad1-Erk1/2 signaling network. PLoS One 2011, 6(7):e21911.
122. Morris E., Chrobak I., Bujor A., Hant F., Mummery C., Ten Dijke P., et al. Endoglin promotes TGF-beta/Smad1 signaling in scleroderma fibroblasts. J Cell Physiol 2011, 226(12):3340-3348.
123. Pannu J., Asano Y., Nakerakanti S., Smith E., Jablonska S., Blaszczyk M., et al. Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate. Arthritis Rheum 2008, 58(8):2528-2537.
124. Sorrentino A., Thakur N., Grimsby S., Marcusson A., von Bulow V., Schuster N., et al. The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. Nat Cell Biol 2008, 10(10):1199-1207.
125. Yamashita M., Fatyol K., Jin C., Wang X., Liu Z., Zhang Y.E. TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-beta. Mol Cell 2008, 31(6):918-924.
126. Varady G., Sarkadi B., Fatyol K. TTRAP is a novel component of the non-canonical TRAF6-TAK1 TGF-beta signaling pathway. PLoS One 2011, 6(9):e25548.
127. Beyer C., Zenzmaier C., Palumbo-Zerr K., Mancuso R., Distler A., Dees C., et al. Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGFbeta signalling. Ann Rheum Dis 2014.
128. Vivar R., Humeres C., Ayala P., Olmedo I., Catalan M., Garcia L., et al. TGF-beta1 prevents simulated ischemia/reperfusion-induced cardiac fibroblast apoptosis by activation of both canonical and non-canonical signaling pathways. Biochim Biophys Acta 2013, 1832(6):754-762.
129. Pannu J., Nakerakanti S., Smith E., ten Dijke P., Trojanowska M. Transforming growth factor-beta receptor type I-dependent fibrogenic gene program is mediated via activation of Smad1 and ERK1/2 pathways. J Biol Chem 2007, 282(14):10405-10413.
130. Samuel G.H., Bujor A.M., Nakerakanti S.S., Hant F.N., Trojanowska M. Autocrine transforming growth factor beta signaling regulates extracellular signal-regulated kinase 1/2 phosphorylation via modulation of protein phosphatase 2A expression in scleroderma fibroblasts. Fibrogenesis Tissue Repair 2010, 3:25.
131. Sato M., Shegogue D., Gore E.A., Smith E.A., McDermott P.J., Trojanowska M. Role of p38 MAPK in transforming growth factor beta stimulation of collagen production by scleroderma and healthy dermal fibroblasts. J Invest Dermatol 2002, 118(4):704-711.
132. Horowitz J.C., Lee D.Y., Waghray M., Keshamouni V.G., Thomas P.E., Zhang H., et al. Activation of the pro-survival phosphatidylinositol 3-kinase/AKT pathway by transforming growth factor-beta1 in mesenchymal cells is mediated by p38 MAPK-dependent induction of an autocrine growth factor. J Biol Chem 2004, 279(2):1359-1367.
133. Ponticos M., Harvey C., Ikeda T., Abraham D., Bou-Gharios G. JunB mediates enhancer/promoter activity of COL1A2 following TGF-beta induction. Nucleic Acids Res 2009, 37(16):5378-5389.
134. Wang S., Wilkes M.C., Leof E.B., Hirschberg R. Noncanonical TGF-beta pathways, mTORC1 and Abl, in renal interstitial fibrogenesis. Am J Physiol Renal Physiol 2010, 298(1):F142-F149.
135. Leask A. Focal adhesion kinase: a key mediator of transforming growth factor beta signaling in fibroblasts. Adv Wound Care (New Rochelle) 2013, 2(5):247-249.
136. Lu T., Tian L., Han Y., Vogelbaum M., Stark G.R. Dose-dependent cross-talk between the transforming growth factor-beta and interleukin-1 signaling pathways. Proc Natl Acad Sci U S A 2007, 104(11):4365-4370.
137. Lam A.P., Flozak A.S., Russell S., Wei J., Jain M., Mutlu G.M., et al. Nuclear beta-catenin is increased in systemic sclerosis pulmonary fibrosis and promotes lung fibroblast migration and proliferation. Am J Respir Cell Mol Biol 2011, 45(5):915-922.
138. Wei J., Fang F., Lam A.P., Sargent J.L., Hamburg E., Hinchcliff M.E., et al. Wnt/beta-catenin signaling is hyperactivated in systemic sclerosis and induces Smad-dependent fibrotic responses in mesenchymal cells. Arthritis Rheum 2012, 64(8):2734-2745.
139. Lam A.P., Herazo-Maya J.D., Sennello J.A., Flozak A.S., Russell S., Mutlu G.M., et al. Wnt coreceptor lrp5 is a driver of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2014, 190(2):185-195.
140. Scheraga R.G., Thannickal V.J. Wnt/beta-catenin and transforming growth factor-beta signaling in pulmonary fibrosis. A case for antagonistic pleiotropy?. Am J Respir Crit Care Med 2014, 190(2):129-131.
141. Zhou B., Liu Y., Kahn M., Ann D.K., Han A., Wang H., et al. Interactions between beta-catenin and transforming growth factor-beta signaling pathways mediate epithelial-mesenchymal transition and are dependent on the transcriptional co-activator cAMP-response element-binding protein (CREB)-binding protein (CBP). J Biol Chem 2012, 287(10):7026-7038.
142. Betsholtz C. Insight into the physiological functions of PDGF through genetic studies in mice. Cytokine Growth Factor Rev 2004, 15(4):215-228.
143. Bonner J.C. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev 2004, 15(4):255-273.
144. Trojanowska M. Role of PDGF in fibrotic diseases and systemic sclerosis. Rheumatology (Oxford) 2008, 47(Suppl. 5):v2-4.
145. Olson L.E., Soriano P. Increased PDGFRalpha activation disrupts connective tissue development and drives systemic fibrosis. Dev Cell 2009, 16(2):303-313.
146. Olson L.E., Soriano P. PDGFRbeta signaling regulates mural cell plasticity and inhibits fat development. Dev Cell 2011, 20(6):815-826.
147. Aono Y., Kishi M., Yokota Y., Azuma M., Kinoshita K., Takezaki A., et al. Role of PDGF/PDGFR axis in the trafficking of circulating fibrocytes in pulmonary fibrosis. Am J Respir Cell Mol Biol 2014.
148. Rajkumar V.S., Shiwen X., Bostrom M., Leoni P., Muddle J., Ivarsson M., et al. Platelet-derived growth factor-beta receptor activation is essential for fibroblast and pericyte recruitment during cutaneous wound healing. Am J Pathol 2006, 169(6):2254-2265.
149. Chen Y.T., Chang F.C., Wu C.F., Chou Y.H., Hsu H.L., Chiang W.C., et al. Platelet-derived growth factor receptor signaling activates pericyte-myofibroblast transition in obstructive and post-ischemic kidney fibrosis. Kidney Int 2011, 80(11):1170-1181.
150. Jakubzick C., Kunkel S.L., Puri R.K., Hogaboam C.M. Therapeutic targeting of IL-4- and IL-13-responsive cells in pulmonary fibrosis. Immunol Res 2004, 30(3):339-349.
151. Kolodsick J.E., Toews G.B., Jakubzick C., Hogaboam C., Moore T.A., McKenzie A., et al. Protection from fluorescein isothiocyanate-induced fibrosis in IL-13-deficient, but not IL-4-deficient, mice results from impaired collagen synthesis by fibroblasts. J Immunol 2004, 172(7):4068-4076.
152. O'Reilly S. Role of interleukin-13 in fibrosis, particularly systemic sclerosis. Biofactors 2013, 39(6):593-596.
153. Luzina I.G., Keegan A.D., Heller N.M., Rook G.A., Shea-Donohue T., Atamas S.P. Regulation of inflammation by interleukin-4: a review of "alternatives". J Leukocyte Biol 2012, 92(4):753-764.
154. Chandriani S., DePianto D.J., N'Diaye E.N., Abbas A.R., Jackman J., Bevers J., et al. Endogenously expressed IL-13Ralpha2 attenuates IL-13-mediated responses but does not activate signaling in human lung fibroblasts. J Immunol 2014, 193(1):111-119.
155. Mentink-Kane M.M., Cheever A.W., Wilson M.S., Madala S.K., Beers L.M., Ramalingam T.R., et al. Accelerated and progressive and lethal liver fibrosis in mice that lack interleukin (IL)-10, IL-12p40, and IL-13Ralpha2. Gastroenterology 2011, 141(6):2200-2209.
156. Brunner S.M., Schiechl G., Kesselring R., Martin M., Balam S., Schlitt H.J., et al. IL-13 signaling via IL-13Ralpha2 triggers TGF-beta1-dependent allograft fibrosis. Transplant Res 2013, 2(1):16.
157. Strober W., Kitani A., Fichtner-Feigl S., Fuss I.J. The signaling function of the IL-13Ralpha2 receptor in the development of gastrointestinal fibrosis and cancer surveillance. Curr Mol Med 2009, 9(6):740-750.
158. George L., Upadhyay S., Ganguly K., Stoeger T. Macrophage polarization in lung biology and diseases. Lung inflammation 2014, InTech.
159. Murray P.J., Allen J.E., Biswas S.K., Fisher E.A., Gilroy D.W., Goerdt S., et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 2014, 41(1):14-20.
160. Boorsma C.E., Draijer C., Melgert B.N. Macrophage heterogeneity in respiratory diseases. Mediators Inflamm 2013, 2013:769214.
161. Bargagli E., Prasse A., Olivieri C., Muller-Quernheim J., Rottoli P. Macrophage-derived biomarkers of idiopathic pulmonary fibrosis. Pulm Med 2011, 2011:717130.
162. Pechkovsky D.V., Prasse A., Kollert F., Engel K.M., Dentler J., Luttmann W., et al. Alternatively activated alveolar macrophages in pulmonary fibrosis-mediator production and intracellular signal transduction. Clin Immunol 2010, 137(1):89-101.
163. Stahl M., Schupp J., Jager B., Schmid M., Zissel G., Muller-Quernheim J., et al. Lung collagens perpetuate pulmonary fibrosis via CD204 and M2 macrophage activation. PLoS One 2013, 8(11):e81382.
164. Barron L., Smith A.M., El Kasmi K.C., Qualls J.E., Huang X., Cheever A., et al. Role of arginase 1 from myeloid cells in th2-dominated lung inflammation. PLoS One 2013, 8(4):e61961.
165. Pesce J.T., Ramalingam T.R., Mentink-Kane M.M., Wilson M.S., El Kasmi K.C., Smith A.M., et al. Arginase-1-expressing macrophages suppress Th2 cytokine-driven inflammation and fibrosis. PLoS Pathog 2009, 5(4):e1000371.
166. Beschin A., De Baetselier P., Van Ginderachter J.A. Contribution of myeloid cell subsets to liver fibrosis in parasite infection. J Pathol 2013, 229(2):186-197.
167. Royce S.G., Cheng V., Samuel C.S., Tang M.L. The regulation of fibrosis in airway remodeling in asthma. Mol Cell Endocrinol 2012, 351(2):167-175.
168. Wilson M.S., Madala S.K., Ramalingam T.R., Gochuico B.R., Rosas I.O., Cheever A.W., et al. Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent. J Exp Med 2010, 207(3):535-552.
169. Christmann R.B., Mathes A., Affandi A.J., Padilla C., Nazari B., Bujor A.M., et al. Thymic stromal lymphopoietin is up-regulated in the skin of patients with systemic sclerosis and induces profibrotic genes and intracellular signaling that overlap with those induced by interleukin-13 and transforming growth factor beta. Arthritis Rheum 2013, 65(5):1335-1346.
170. Hams E., Armstrong M.E., Barlow J.L., Saunders S.P., Schwartz C., Cooke G., et al. IL-25 and type 2 innate lymphoid cells induce pulmonary fibrosis. Proc Natl Acad Sci U S A 2014, 111(1):367-372.
171. McHedlidze T., Waldner M., Zopf S., Walker J., Rankin A.L., Schuchmann M., et al. Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis. Immunity 2013, 39(2):357-371.
172. Rankin A.L., Mumm J.B., Murphy E., Turner S., Yu N., McClanahan T.K., et al. IL-33 induces IL-13-dependent cutaneous fibrosis. J Immunol 2010, 184(3):1526-1535.
173. Datta A., Alexander R., Sulikowski M.G., Nicholson A.G., Maher T.M., Scotton C.J., et al. Evidence for a functional thymic stromal lymphopoietin signaling axis in fibrotic lung disease. J Immunol 2013, 191(9):4867-4879.
174. Luzina I.G., Pickering E.M., Kopach P., Kang P.H., Lockatell V., Todd N.W., et al. Full-length IL-33 promotes inflammation but not Th2 response in vivo in an ST2-independent fashion. J Immunol 2012, 189(1):403-410.
175. Luzina I.G., Kopach P., Lockatell V., Kang P.H., Nagarsekar A., Burke A.P., et al. Interleukin-33 potentiates bleomycin-induced lung injury. Am J Respir Cell Mol Biol 2013, 49(6):999-1008.
176. Zhu J., Carver W. Effects of interleukin-33 on cardiac fibroblast gene expression and activity. Cytokine 2012, 58(3):368-379.
177. Seki K., Sanada S., Kudinova A.Y., Steinhauser M.L., Handa V., Gannon J., et al. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail 2009, 2(6):684-691.
178. Sanada S., Hakuno D., Higgins L.J., Schreiter E.R., McKenzie A.N., Lee R.T. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007, 117(6):1538-1549.
179. Chen C.C., Lau L.F. Functions and mechanisms of action of CCN matricellular proteins. Int J Biochem Cell Biol 2009, 41(4):771-783.
180. Brigstock D.R. Connective tissue growth factor (CCN2, CTGF) and organ fibrosis: lessons from transgenic animals. J Cell Commun Signal 2010, 4(1):1-4.
181. Mori T., Kawara S., Shinozaki M., Hayashi N., Kakinuma T., Igarashi A., et al. Role and interaction of connective tissue growth factor with transforming growth factor-beta in persistent fibrosis: a mouse fibrosis model. J Cell Physiol 1999, 181(1):153-159.
182. Bujor A.M., Nakerakanti S., Morris E., Hant F.N., Trojanowska M. Akt inhibition up-regulates MMP1 through a CCN2-dependent pathway in human dermal fibroblasts. Exp Dermatol 2010, 19(4):347-354.
183. Sonnylal S., Shi-Wen X., Leoni P., Naff K., Van Pelt C.S., Nakamura H., et al. Selective expression of connective tissue growth factor in fibroblasts in vivo promotes systemic tissue fibrosis. Arthritis Rheum 2010, 62(5):1523-1532.
184. Yang J., Velikoff M., Canalis E., Horowitz J.C., Kim K.K. Activated alveolar epithelial cells initiate fibrosis through autocrine and paracrine secretion of connective tissue growth factor. Am J Physiol Lung Cell Mol Physiol 2014, 306(8):L786-796.
185. Bonniaud P., Martin G., Margetts P.J., Ask K., Robertson J., Gauldie J., et al. Connective tissue growth factor is crucial to inducing a profibrotic environment in "fibrosis-resistant" BALB/c mouse lungs. Am J Respir Cell Mol Biol 2004, 31(5):510-516.
186. Liu S., Herault Y., Pavlovic G., Leask A. Skin progenitor cells contribute to bleomycin-induced skin fibrosis. Arthritis Rheumatol 2014, 66(3):707-713.
187. Mercer P.F., Johns R.H., Scotton C.J., Krupiczojc M.A., Konigshoff M., Howell D.C., et al. Pulmonary epithelium is a prominent source of proteinase-activated receptor-1-inducible CCL2 in pulmonary fibrosis. Am J Respir Crit Care Med 2009, 179(5):414-425.
188. Osterholzer J.J., Olszewski M.A., Murdock B.J., Chen G.H., Erb-Downward J.R., Subbotina N., et al. Implicating exudate macrophages and Ly-6C(high) monocytes in CCR2-dependent lung fibrosis following gene-targeted alveolar injury. J Immunol 2013, 190(7):3447-3457.
189. Sahin H., Wasmuth H.E. Chemokines in tissue fibrosis. Biochim Biophys Acta 2013, 1832(7):1041-1048.
190. Strieter R.M., Gomperts B.N., Keane M.P. The role of CXC chemokines in pulmonary fibrosis. J Clin Invest 2007, 117(3):549-556.
191. Lin C.H., Shih C.H., Tseng C.C., Yu C.C., Tsai Y.J., Bien M.Y., et al. CXCL12 induces connective tissue growth factor expression in human lung fibroblasts through the Rac1/ERK, JNK, and AP-1 pathways. PLoS One 2014, 9(8):e104746.
192. Le T.T., Karmouty-Quintana H., Melicoff E., Weng T., Chen N.Y., Pedroza M., et al. Blockade of IL-6 trans signaling attenuates pulmonary fibrosis. J Immunol 2014.
193. O'Reilly S., Ciechomska M., Cant R., van Laar J.M. Interleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor-beta (TGF-beta) signaling promoting SMAD3 activation and fibrosis via Gremlin protein. J Biol Chem 2014, 289(14):9952-9960.
194. O'Donoghue R.J., Knight D.A., Richards C.D., Prele C.M., Lau H.L., Jarnicki A.G., et al. Genetic partitioning of interleukin-6 signalling in mice dissociates Stat3 from Smad3-mediated lung fibrosis. EMBO Mol Med 2012, 4(9):939-951.
195. Scaffidi A.K., Mutsaers S.E., Moodley Y.P., McAnulty R.J., Laurent G.J., Thompson P.J., et al. Oncostatin M stimulates proliferation, induces collagen production and inhibits apoptosis of human lung fibroblasts. Br J Pharmacol 2002, 136(5):793-801.
196. Ihn H., LeRoy E.C., Trojanowska M. Oncostatin M stimulates transcription of the human alpha2(I) collagen gene via the Sp1/Sp3-binding site. J Biol Chem 1997, 272(39):24666-24672.
197. Nagahama K.Y., Togo S., Holz O., Magnussen H., Liu X., Seyama K., et al. Oncostatin M modulates fibroblast function via signal transducers and activators of transcription proteins-3. Am J Respir Cell Mol Biol 2013, 49(4):582-591.
198. Mozaffarian A., Brewer A.W., Trueblood E.S., Luzina I.G., Todd N.W., Atamas S.P., et al. Mechanisms of oncostatin M-induced pulmonary inflammation and fibrosis. J Immunol 2008, 181(10):7243-7253.
199. Fritz D.K., Kerr C., Fattouh R., Llop-Guevara A., Khan W.I., Jordana M., et al. A mouse model of airway disease: oncostatin M-induced pulmonary eosinophilia, goblet cell hyperplasia, and airway hyperresponsiveness are STAT6 dependent, and interstitial pulmonary fibrosis is STAT6 independent. J Immunol 2011, 186(2):1107-1118.
200. Wong S., Botelho F.M., Rodrigues R.M., Richards C.D. Oncostatin M overexpression induces matrix deposition, STAT3 activation, and SMAD1 Dysregulation in lungs of fibrosis-resistant BALB/c mice. Lab Invest 2014, 94(9):1003-1016.
201. Hamaguchi Y., Fujimoto M., Matsushita T., Hasegawa M., Takehara K., Sato S. Elevated serum insulin-like growth factor (IGF-1) and IGF binding protein-3 levels in patients with systemic sclerosis: possible role in development of fibrosis. J Rheumatol 2008, 35(12):2363-2371.
202. Hsu E., Feghali-Bostwick C.A. Insulin-like growth factor-II is increased in systemic sclerosis-associated pulmonary fibrosis and contributes to the fibrotic process via Jun N-terminal kinase- and phosphatidylinositol-3 kinase-dependent pathways. Am J Pathol 2008, 172(6):1580-1590.
203. Aston C., Jagirdar J., Lee T.C., Hur T., Hintz R.L., Rom W.N. Enhanced insulin-like growth factor molecules in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1995, 151(5):1597-1603.
204. Veraldi K.L., Feghali-Bostwick C.A. Insulin-like growth factor binding proteins-3 and -5: central mediators of fibrosis and promising new therapeutic targets. Open Rheumatol J 2012, 6:140-145.
205. Baxter R.C. Insulin-like growth factor binding protein-3 (IGFBP-3): novel ligands mediate unexpected functions. J Cell Commun Signal 2013, 7(3):179-189.
206. Vazquez-Lombardi R., Roome B., Christ D. Molecular engineering of therapeutic cytokines. Antibodies 2013, 2(3):426-451.
207. Jinnin M., Ihn H., Mimura Y., Asano Y., Yamane K., Tamaki K. Effects of hepatocyte growth factor on the expression of type I collagen and matrix metalloproteinase-1 in normal and scleroderma dermal fibroblasts. J Invest Dermatol 2005, 124(2):324-330.
208. Bogatkevich G.S., Ludwicka-Bradley A., Highland K.B., Hant F., Nietert P.J., Singleton C.B., et al. Impairment of the antifibrotic effect of hepatocyte growth factor in lung fibroblasts from African Americans: possible role in systemic sclerosis. Arthritis Rheum 2007, 56(7):2432-2442.
209. King T.E., Albera C., Bradford W.Z., Costabel U., Hormel P., Lancaster L., et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009, 374(9685):222-228.
210. Bansal R., Prakash J., De Ruiter M., Poelstra K. Interferon gamma peptidomimetic targeted to hepatic stellate cells ameliorates acute and chronic liver fibrosis in vivo. J Control Release 2014, 179:18-24.
211. Okayama K., Azuma J., Dosaka N., Iekushi K., Sanada F., Kusunoki H., et al. Hepatocyte growth factor reduces cardiac fibrosis by inhibiting endothelial-mesenchymal transition. Hypertension 2012, 59(5):958-965.
212. Chakraborty S., Chopra P., Hak A., Dastidar S.G., Ray A. Hepatocyte growth factor is an attractive target for the treatment of pulmonary fibrosis. Expert Opin Invest Drugs 2013, 22(4):499-515.
213. Shukla M.N., Rose J.L., Ray R., Lathrop K.L., Ray A., Ray P. Hepatocyte growth factor inhibits epithelial to myofibroblast transition in lung cells via Smad7. Am J Respir Cell Mol Biol 2009, 40(6):643-653.
214. Marchand-Adam S., Fabre A., Mailleux A.A., Marchal J., Quesnel C., Kataoka H., et al. Defect of pro-hepatocyte growth factor activation by fibroblasts in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006, 174(1):58-66.
215. Phin S., Marchand-Adam S., Fabre A., Marchal-Somme J., Bantsimba-Malanda C., Kataoka H., et al. Imbalance in the pro-hepatocyte growth factor activation system in bleomycin-induced lung fibrosis in mice. Am J Respir Cell Mol Biol 2010, 42(3):286-293.
216. Landgraf K.E., Steffek M., Quan C., Tom J., Yu C., Santell L., et al. An allosteric switch for pro-HGF/Met signaling using zymogen activator peptides. Nat Chem Biol 2014, 10(7):567-573.
217. Hahn W., Pyun W.B., Kim D.S., Yoo W.S., Lee S.D., Won J.H., et al. Enhanced cardioprotective effects by coexpression of two isoforms of hepatocyte growth factor from naked plasmid DNA in a rat ischemic heart disease model. J Gene Med 2011, 13(10):549-555.
218. Jun J.I., Lau L.F. The matricellular protein CCN1 induces fibroblast senescence and restricts fibrosis in cutaneous wound healing. Nat Cell Biol 2010, 12(7):676-685.
219. Kim K.H., Chen C.C., Monzon R.I., Lau L.F. Matricellular protein CCN1 promotes regression of liver fibrosis through induction of cellular senescence in hepatic myofibroblasts. Mol Cell Biol 2013, 33(10):2078-2090.
220. Borkham-Kamphorst E., Schaffrath C., Van de Leur E., Haas U., Tihaa L., Meurer S.K., et al. The anti-fibrotic effects of CCN1/CYR61 in primary portal myofibroblasts are mediated through induction of reactive oxygen species resulting in cellular senescence, apoptosis and attenuated TGF-beta signaling. Biochim Biophys Acta 2014, 1843(5):902-914.
221. Simonian P.L., Wehrmann F., Roark C.L., Born W.K., O'Brien R.L., Fontenot A.P. Gammadelta T cells protect against lung fibrosis via IL-22. J Exp Med 2010, 207(10):2239-2253.
222. Liang M., Wang J., Chu H., Zhu X., He H., Liu Q., et al. Interleukin-22 inhibits bleomycin-induced pulmonary fibrosis. Mediators Inflamm 2013, 2013:209179.
223. Pociask D.A., Chen K., Choi S.M., Oury T.D., Steele C., Kolls J.K. Gammadelta T cells attenuate bleomycin-induced fibrosis through the production of CXCL10. Am J Pathol 2011, 178(3):1167-1176.
224. Jiang D., Liang J., Hodge J., Lu B., Zhu Z., Yu S., et al. Regulation of pulmonary fibrosis by chemokine receptor CXCR3. J Clin Invest 2004, 114(2):291-299.
225. Jiang D., Liang J., Campanella G.S., Guo R., Yu S., Xie T., et al. Inhibition of pulmonary fibrosis in mice by CXCL10 requires glycosaminoglycan binding and syndecan-4. J Clin Invest 2010, 120(6):2049-2057.
226. Xu L., Xiong S., Guo R., Yang Z., Wang Q., Xiao F., et al. Transforming growth factor beta3 attenuates the development of radiation-induced pulmonary fibrosis in mice by decreasing fibrocyte recruitment and regulating IFN-gamma/IL-4 balance. Immunol Lett 2014.
227. Zhang L., Yan J.W., Wang Y.J., Wan Y.N., Wang B.X., Tao J.H., et al. Association of interleukin 1 family with systemic sclerosis. Inflammation 2014, 37(4):1213-1220.
228. Mia M.M., Boersema M., Bank R.A. Interleukin-1beta attenuates myofibroblast formation and extracellular matrix production in dermal and lung fibroblasts exposed to transforming growth factor-beta1. PLoS One 2014, 9(3):e91559.
229. Barbarin V., Xing Z., Delos M., Lison D., Huaux F. Pulmonary overexpression of IL-10 augments lung fibrosis and Th2 responses induced by silica particles. Am J Physiol Lung Cell Mol Physiol 2005, 288(5):L841-848.
230. Sun L., Louie M.C., Vannella K.M., Wilke C.A., LeVine A.M., Moore B.B., et al. New concepts of IL-10-induced lung fibrosis: fibrocyte recruitment and M2 activation in a CCL2/CCR2 axis. Am J Physiol Lung Cell Mol Physiol 2011, 300(3):L341-353.
231. Nakagome K., Dohi M., Okunishi K., Tanaka R., Miyazaki J., Yamamoto K. In vivo IL-10 gene delivery attenuates bleomycin induced pulmonary fibrosis by inhibiting the production and activation of TGF-beta in the lung. Thorax 2006, 61(10):886-894.
232. Shi J., Li J., Guan H., Cai W., Bai X., Fang X., et al. Anti-fibrotic actions of interleukin-10 against hypertrophic scarring by activation of PI3K/AKT and STAT3 signaling pathways in scar-forming fibroblasts. PLoS One 2014, 9(5):e98228.
233. Kradin R.L., Sakamoto H., Jain F., Zhao L.H., Hymowitz G., Preffer F. IL-10 inhibits inflammation but does not affect fibrosis in the pulmonary response to bleomycin. Exp Mol Pathol 2004, 76(3):205-211.
234. Mi S., Li Z., Yang H.Z., Liu H., Wang J.P., Ma Y.G., et al. Blocking IL-17A promotes the resolution of pulmonary inflammation and fibrosis via TGF-beta1-dependent and -independent mechanisms. J Immunol 2011, 187(6):3003-3014.
235. Lo Re S., Dumoutier L., Couillin I., Van Vyve C., Yakoub Y., Uwambayinema F., et al. IL-17A-producing gammadelta T and Th17 lymphocytes mediate lung inflammation but not fibrosis in experimental silicosis. J Immunol 2010, 184(11):6367-6377.
236. Nakashima T., Jinnin M., Yamane K., Honda N., Kajihara I., Makino T., et al. Impaired IL-17 signaling pathway contributes to the increased collagen expression in scleroderma fibroblasts. J Immunol 2012, 188(8):3573-3583.
237. Luzina I.G., Highsmith K., Pochetuhen K., Nacu N., Rao J.N., Atamas S.P. PKCalpha mediates CCL18-stimulated collagen production in pulmonary fibroblasts. Am J Respir Cell Mol Biol 2006, 35(3):298-305.
238. Luzina I.G., Tsymbalyuk N., Choi J., Hasday J.D., Atamas S.P. CCL18-stimulated upregulation of collagen production in lung fibroblasts requires Sp1 signaling and basal Smad3 activity. J Cell Physiol 2006, 206(1):221-228.
239. Atamas S.P., Luzina I.G., Choi J., Tsymbalyuk N., Carbonetti N.H., Singh I.S., et al. Pulmonary and activation-regulated chemokine stimulates collagen production in lung fibroblasts. Am J Respir Cell Mol Biol 2003, 29(6):743-749.
240. Luzina I.G., Todd N.W., Nacu N., Lockatell V., Choi J., Hummers L.K., et al. Regulation of pulmonary inflammation and fibrosis through expression of integrins alphaVbeta3 and alphaVbeta5 on pulmonary T lymphocytes. Arthritis Rheum 2009, 60(5):1530-1539.
241. Pochetuhen K., Luzina I.G., Lockatell V., Choi J., Todd N.W., Atamas S.P. Complex regulation of pulmonary inflammation and fibrosis by CCL18. Am J Pathol 2007, 171(2):428-437.
242. Luzina I.G., Papadimitriou J.C., Anderson R., Pochetuhen K., Atamas S.P. Induction of prolonged infiltration of T lymphocytes and transient T lymphocyte-dependent collagen deposition in mouse lungs following adenoviral gene transfer of CCL18. Arthritis Rheum 2006, 54(8):2643-2655.
243. Ahluwalia N., Shea B.S., Tager A.M. New therapeutic targets in idiopathic pulmonary fibrosis: aiming to rein in runaway wound healing responses. Am J Respir Crit Care Med 2014.